Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: A randomized, investigator-blinded, placebo-controlled trial

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 10, 2005, Pages 1231-1239

  Ott, E A ^a,b,c   Mazzoleni, L E ^a,b   Edelweiss, M I ^a,b   Sander, G B ^a,b   Wortmann, A C ^a,b   Theil, A L ^a   Somm, G ^a   Cartell, A ^a   Rivero, L F ^a   Uchoa D M ^a   Francesconi, C F ^a,b   Prolla, J C ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c School of Medicine ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; DOMPERIDONE; LANSOPRAZOLE; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RISK ASSESSMENT; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AMOXICILLIN; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; DYSPEPSIA; ESOPHAGITIS, PEPTIC; FOLLOW-UP STUDIES; HEARTBURN; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; OMEPRAZOLE; RISK ASSESSMENT; SINGLE-BLIND METHOD;

EID: 21144449754     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02461.x     Document Type: Article

References (64)

1. Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis (Letter). Lancet 1983; 1: 1273-4.
2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9.
3. Walsh JH, Petersen WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-1005.
4. Rokkas T, Karameris A, Mavrogeorgias A, et al. Eradication of Helicobacter pylori reduces possibility of re-bleeding in peptic ulcer disease. Gastrointest Endosc 1995; 41: 1-4.
5. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-7.
6. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995; 122: 767-9.
7. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995; 345: 1591-4.
8. Uemura N, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic re-section of early gastric cancer in Japan. Gastroenterol Clin North Am 2000; 348: 150-4.
9. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
10. Malfertheiner P, Mégraud F, O'Morain C, et al. The European Helicobacter pylori Study Group. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2 - 2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
11. Coelho LGV, León-Barúa R, Quigley EMM, et al. Latin-American Consensus Conference on Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 2688-91.
12. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330-8.
13. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12.
14. Binder HJ. H. pylori and non-ulcer dyspepsia: not guilty as charged. Gastroenterology 1999; 117: 270-2.
15. Strauss RM, Wang TC, Kelsey PB, et al. Association of Helicobacter pylori infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. Am J Med 1990; 89: 464-9.
16. Gilvarry J, Buckley MJM, Beatti S, et al. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1997; 32: 535-40.
17. Mccoll K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with non-ulcer dyspepsia. N Engl J Med 1999; 339: 1869-74.
18. Malfertheiner P, Mossmer J, Fischbach W, et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 615-25.
19. Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with non-ulcer dyspepsia. N Engl J Med 1998; 339: 1875-81.
20. Talley NJ, Vakil N, Ballard ED, et al. Absence of benefit of eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. N Engl J Med 1999; 341: 1106-11.
21. Talley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 month follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 1999; 318: 833-7.
22. Miwa H, Hirai S, Nagahara A, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients - a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000; 14: 317-24.
23. Jaakkimainen L, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ 1999; 319: 1040-4.
24. Laine L, Schoenfeld P, Fennerty M. Therapy for Helicobacter pylori in patients with non-ulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134: 361-9.
25. Koeltz HR, Arnold R, Stolte M, et al. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomized trial with a six month follow up. Gut 2003; 52: 40-6.
26. van Zanten VS, Fedorak RN, Lambert J, et al. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol 2003; 98: 1963-9.
27. Kamada T, Haruma K, Hata J, et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther 2003; 18: 245-52.
28. Moayyedi P, Decks J, Talley NJ, et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621-6.
29. O'Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease - clinical implications and management. Aliment Pharmacol Ther 1999; 13: 117-27.
30. Malfertheiner P, O'Connor HJ, Genta RM, et al. Symposium: Helicobacter pylori and clinical risks - focus on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16 (Suppl. 3): 1-10.
31. Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastro-oesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol 1998; 93: 1800-2.
32. Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 1997; 41: 277-80.
33. Labenz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux oesophagitis. Gastroenterology 1997; 112: 1442-7.
34. Hamada H, Haruma M, Mihara M, et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14: 729-35.
35. Befrits R, Sjostedt S, Odman B, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastro-oesophageal reflux disease. Helicobacter 2000; 5: 202-6.
36. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive oesophagitis and gastro-oesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97: 2992-7.
37. Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: The relationship between Helicobacter pylori infection and oesophageal reflux disease. Aliment Pharmacol Ther 2003; 18: 279-89.
38. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 45-51.
39. Malfertheiner P, Dent J, Zeijlon L, et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme. Aliment Pharmacol Ther 2002; 16: 1431-42.
40. Raghunath AS, Hungin APS, Wooff D, et al. Systematic review: The effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004; 20: 733-44.
41. Moayyedi P, Bardhan C, Toung L, et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastro-oesophageal reflux disease. Gastroenterology 2001; 121: 1120-6.
42. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomized controlled trial. Lancet 2001; 357: 1738-42.
43. Laine L, Dhir V. Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Aliment Pharmacol Ther 2002; 16: 1143-8.
44. Adamek RJ, Behrendt J, Wenzel C. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine. Eur J Gastroenterol Hepatol 2001; 13: 811-7.
45. Wu JCY, Chan FKL, Ching JYL, et al. Effect of Helicobacter pylori eradication on gastro-oesophageal reflux disease: a double blind, placebo controlled, randomized trial. Gut 2004; 53: 174-9.
46. Harvey RF, Lane JA, Murray LJ, et al. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter project. BMJ 2004; 328: 1417-20.
47. Kuipers EJ, NeKs GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomized controlled trial. Gut 2004; 53: 12-20.
48. Talley NJ, Janssens J, Lauritsen K, et al. No increase in reflux symptoms or oesophagitis in patients with no-ulcer dyspepsia 12 months after Helicobacter pylori eradication. A randomized double-blind placebo-controlled trial [abstract]. Gastroenterology 1998; 114: A306.
49. Talley NJ, Colin-Jones DG, Koch KI, et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145-60.
50. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
51. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of oesophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
52. Tytgat GN. The Sydney system: endoscopic division. Endoscopic appearances in gastritis/duodenitis. J Gastroenterol Hepatol 1991; 6: 223-34.
53. Chen XY, van Der Hulst RW, Shi Y, et al. Comparison of pre-cancerous conditions: atrophy and intestinal metaplasia in Helicobacter pylori gastritis among Chinese and Dutch patients. J Clin Pathol 2001; 54: 367-70.
54. Feldman M, Cryer B, McArthur KE, et al. Effects of aging and gastritis on gastric acid and pepsin secretion in humans: a prospective study. Gastroenterology 1996; 110: 1043-52.
55. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 49: 330-4.
56. El-Serag HB, Sonnenberg A, Jamal MM, et al. Corpus gastritis is protective against reflux oesophagitis. Gut 1999; 45: 181-5.
57. Vicari JJ, Peek RM, Falk GE, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastro-oesophageal reflux disease. Gastroenterology 1998; 115: 50-7.
58. Kyzekova J, Mour J. The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and Helicobacter pylori infection. Prospective randomized intervention study. Hepatogastroenterology 1999; 46: 2048-56.
59. El-Omar E, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic acid hyposecretion. Gastroenterology 1997; 113: 15-24.
60. Savarino V, Mela GS, Zentilin P, et al. Histological and functional recovery in patients with multifocal atrophic gastritis after eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol 1999; 31: 4-8.
61. Tucci A, Biasco G. Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis. N Engl J Med 1997; 336: 957-8.
62. Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus - evaluation of 24 h pH monitoring. Aliment Pharmacol Ther 1999; 13: 155-62.
63. Koike T, Ohara S, Sekine H, et al. Increased gastric acid secretion after Helicobacter pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 813-20.
64. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. 2): II37-42.